Ecolab Inc. — Q3 2021 Form 10-Q
Business context and reporting period
Quarter ended September 30, 2021; comparisons are with Q3 and the first nine months of 2020. Ecolab provides cleaning, sanitizing, water-treatment and related services. Its reportable segments are Global Industrial, Global Institutional & Specialty, and Global Healthcare & Life Sciences, plus Other. ChampionX was separated in June 2020 and is reported as discontinued operations; prior-period continuing results have been recast.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Net sales | $3,320.8 million | $3,018.6 million | $9,368.5 million | $8,724.9 million |
| Operating income | $465.8 million | $411.4 million | $1,210.9 million | $979.6 million |
| Net income attributable to Ecolab from continuing operations | $324.5 million | $246.2 million | $828.9 million | $667.1 million |
| Diluted continuing-operations EPS | $1.12 | $0.85 | $2.87 | $2.29 |
| Reported gross margin | 39.3% | 41.4% | 40.5% | 41.3% |
| Reported operating margin | 14.0% | 13.6% | 12.9% | 11.2% |
Q3 fixed-currency sales grew 8% (8% acquisition-adjusted); volume contributed 6% and pricing 3%. Reported sales increased 10%, including a favorable 2% currency effect. Adjusted diluted continuing-operations EPS, excluding special charges and discrete tax items, rose 20% to $1.38. These adjusted figures are non-GAAP.
Q3 segment sales at fixed currency: Industrial grew 7% to $1,620 million; Institutional & Specialty grew 18% to $1,077 million; Healthcare & Life Sciences declined 13% to $290 million; Other grew 13% to $326 million. Industrial operating income fell 11% to $268 million, reflecting higher delivered product costs, Hurricane Ida and mix. Institutional & Specialty operating income rose to $197 million from $84 million amid market recovery, volume, pricing and favorable mix. Healthcare & Life Sciences operating income fell 46% to $37 million, in part against unusually strong pandemic-related demand in 2020.
For the first nine months, operating cash flow was $1,421 million, versus $1,092 million; capital expenditures were $424 million, versus $362 million. Cash was $897.9 million at September 30, down from $1,260.2 million at year-end 2020. Total debt was $5,950.5 million, down from $6,686.6 million; net debt was $5,052.6 million and net debt/EBITDA was 2.0x, compared with 2.4x at year-end. Current assets were $4,986.8 million and current liabilities $2,894.5 million. Ecolab reported $5,931.8 million of long-term debt, no commercial paper outstanding, and no borrowings under its $2.0 billion credit facility. It was in compliance with debt covenants.
Material changes, outlook, and risks
- Adjusted gross margin was 40.9% in Q3, down from 41.7%; management attributed the decline to delivered-product cost inflation and Hurricane Ida, which outweighed pricing and volume benefits. SG&A as a share of sales improved to 25.1% from 26.6%.
- Special charges and gains totaled $98.5 million in Q3 and $171.8 million year to date. A $50 million reserve for excess sanitizer inventory and disposal costs was the principal Q3 item. Other significant items included debt-refinancing costs, pension-settlement expenses, restructuring, COVID-related costs and legal charges.
- Management expected continued, uneven recovery in the U.S. and Europe, with other regions following, and continued substantial delivered-product cost inflation. It expected Q4 earnings growth in the double digits, but below Q3 growth. Hurricane Ida reduced Q3 reported and adjusted diluted EPS by an estimated $0.03.
- COVID-19 risks include renewed restrictions or variants, uneven customer recovery, supply shortages and inflation, and possible operational disruption. Ecolab also cited risks from vaccination requirements applicable to certain federal-contract work, raw-material availability and costs, foreign exchange, cybersecurity and ERP implementation, litigation, environmental matters, and tax and regulatory uncertainties.
- Restructuring programs remained in progress. Institutional Advancement costs were estimated at $80 million through 2023, with about $50 million annual savings expected by 2024; Accelerate 2020 costs were estimated at $255 million through 2022, with about $315 million annual savings expected by 2022. Actual costs and savings may differ.
- After quarter-end, Ecolab agreed on October 28, 2021 to acquire Purolite for $3.7 billion, subject to adjustments. The acquisition had not closed as of the filing date. Ecolab also reported a subsequent interest-rate swap.
- Legal and environmental matters include participation in remediation at approximately 30 locations. Management said it did not believe material loss beyond accrued amounts was reasonably possible for its current legal matters, while noting adverse developments could result in additional charges. The interim financial statements received a limited review, not an audit.
Important facts for investors to verify
- Whether pricing can catch up with input-cost inflation and restore gross margins, especially in Industrial.
- Whether the Q4 double-digit earnings-growth outlook was achieved and how COVID conditions and customer reopening trends evolved.
- The sanitizer inventory reserve’s final cash and earnings impact, and the timing and realized savings of restructuring programs.
- Purolite transaction financing, final purchase price, closing conditions, integration costs and expected contribution.
- Debt repayment and refinancing terms, interest-rate exposure, and whether leverage and liquidity remain consistent with management’s expectations.
- Potential changes in litigation, environmental remediation, uncertain tax positions, vaccination-related obligations and ERP/cybersecurity risks.